US 12,458,660 B2
Methods of attenuating an immune response by inhibition of BFL1
David A. Hildeman, Cincinnati, OH (US); Andrew Herr, Cincinnati, OH (US); Suhas G. Kallapur, Cincinnati, OH (US); Jarek Meller, Cincinnati, OH (US); and Alexander Thorman, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Filed by CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH (US)
Filed on Dec. 19, 2022, as Appl. No. 18/083,617.
Application 18/083,617 is a division of application No. 15/733,346, granted, now 11,541,073, previously published as PCT/US2019/013470, filed on Jan. 14, 2019.
Claims priority of provisional application 62/664,367, filed on Apr. 30, 2018.
Claims priority of provisional application 62/616,538, filed on Jan. 12, 2018.
Prior Publication US 2023/0131243 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/713 (2006.01); A61K 31/655 (2006.01); A61K 31/7105 (2006.01); C07K 16/18 (2006.01); C12N 15/113 (2010.01); A61K 9/127 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 31/713 (2013.01) [A61K 31/655 (2013.01); A61K 31/7105 (2013.01); C07K 16/18 (2013.01); C12N 15/113 (2013.01); A61K 9/127 (2013.01); B82Y 5/00 (2013.01); C12N 2310/14 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A method for treating an autoimmune disease or allergic disorder characterized by neutrophil-mediated inflammation in a subject in need of such treatment, the method comprising administering to the subject an inhibitor of BFL1, wherein the inhibitor is a small organic molecule that binds to the P2 or P4 pocket, or both, of the BH3 domain of BFL1.